We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-7.84%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.19B
AUM Growth
+$85M
Cap. Flow
-$603M
Cap. Flow %
-18.9%
Top 10 Hldgs %
36.68%
Holding
85
New
17
Increased
26
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$75.5M
2
SYRE icon
Spyre Therapeutics
SYRE
+$67.4M
3
EXAS
Exact Sciences
EXAS
+$62.8M
4
INSP icon
Inspire Medical Systems
INSP
+$52.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$50.1M

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$50.9M
2
PCVX icon
Vaxcyte
PCVX
+$27.5M
3
CGEM icon
Cullinan Oncology
CGEM
+$22.7M
4
TRML
Tourmaline Bio
TRML
+$20.8M
5
ARGX icon
argenx
ARGX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 60.98%
2 Miscellaneous 38.71%
3 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.7B
$104M 3.28%
759,009
+28,800
+4% +$3.95M
CGON icon
2
CG Oncology
CGON
$6.59B
$104M 3.28%
3,309,507
+2,179,272
+193% +$75.5M
XENE icon
3
Xenon Pharmaceuticals
XENE
$5.81B
$99.8M 3.13%
2,560,573
+1,252,562
+96% +$50.1M
APGE icon
4
Apogee Therapeutics
APGE
$10.2B
$94.1M 2.95%
2,392,042
+549,527
+30% +$26.7M
GH icon
5
Guardant Health
GH
$21.7B
$81.1M 2.54%
2,807,968
+331,164
+13% +$7.71M
LEGN icon
6
Legend Biotech
LEGN
$3.87B
$74M 2.32%
1,669,720
+425,925
+34% +$19.6M
ARGX icon
7
argenx
ARGX
$64B
$71.8M 2.25%
166,924
-52,900
-24% -$20.2M
ALGN icon
8
Align Technology
ALGN
$11.2B
$66.4M 2.08%
275,207
+105,955
+63% +$29.5M
MRVI icon
9
Maravai LifeSciences
MRVI
$1.14B
$64.6M 2.03%
9,024,037
+1,802,077
+25% +$15.6M
PCVX icon
10
Vaxcyte
PCVX
$8.9B
$61M 1.91%
808,303
-404,400
-33% -$27.5M
SYRE icon
11
Spyre Therapeutics
SYRE
$7.97B
$59.1M 1.85%
2,514,538
+1,999,538
+388% +$67.4M
GKOS icon
12
Glaukos
GKOS
$10.6B
$58.8M 1.84%
496,576
+45,900
+10% +$4.87M
VKTX icon
13
Viking Therapeutics
VKTX
$3.75B
$58.7M 1.84%
1,106,905
+393,805
+55% +$25.8M
IRTC icon
14
iRhythm Holdings
IRTC
$3.96B
$56.7M 1.78%
526,357
+43,100
+9% +$4.4M
INSP icon
15
Inspire Medical Systems
INSP
$1.78B
$50.8M 1.59%
379,443
+277,951
+274% +$52.6M
EXAS
16
DELISTED
Exact Sciences
EXAS
$48.2M 1.51%
+1,141,678
New +$62.8M
KROS icon
17
Keros Therapeutics
KROS
$219M
$44.9M 1.41%
982,209
+244,830
+33% +$13.2M
ISRG icon
18
Intuitive Surgical
ISRG
$132B
$44.7M 1.4%
100,500
– –
DAWN
19
DELISTED
Day One Biopharmaceuticals
DAWN
$41.8M 1.31%
3,035,904
+862,200
+40% +$12.6M
RGEN icon
20
Repligen
RGEN
$9.95B
$40.8M 1.28%
323,509
+180,673
+126% +$28.3M
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$40.8M 1.28%
2,898,639
+230,090
+9% +$3.75M
TMO icon
22
Thermo Fisher Scientific
TMO
$230B
$39M 1.22%
70,449
+23,300
+49% +$13.3M
KNSA icon
23
Kiniksa Pharmaceuticals
KNSA
$6.09B
$38.4M 1.21%
2,058,303
+665,587
+48% +$12.5M
PEN icon
24
Penumbra
PEN
$12.7B
$38.3M 1.2%
212,594
-83,298
-28% -$16.6M
KIDS icon
25
OrthoPediatrics
KIDS
$617M
$31.9M 1%
1,107,770
– –
1
2 3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q2 2024 Portfolio in Review

As of Q2 2024, Braidwell held 85 positions worth $3.19B, up 2.7% from $3.1B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $603M in Q2 2024, closing 10 positions and reducing 11 holdings. Its most notable exit was Tourmaline Bio, an estimated $20.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Exact Sciences worth $48.2M.

  • Braidwell's largest Q2 2024 buy was Exact Sciences: 1,141,678 shares worth $48.2M.
  • Braidwell added most to CG Oncology in Q2 2024, an estimated $75.5M increase.
  • Braidwell's biggest Q2 2024 reduction was Transmedics, cutting an estimated $50.9M.
  • Braidwell fully exited Tourmaline Bio in Q2 2024, selling an estimated $20.8M.
  • Braidwell's ten largest holdings make up 37% of its $3.19B portfolio in Q2 2024.
  • Braidwell opened 17 new positions and closed 10 in Q2 2024.
  • Braidwell's portfolio value rose 2.7% quarter-over-quarter to $3.19B.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.